News & Updates

Continued treatment with tumor necrosis factor (TNF) inhibitors after 24 weeks of pregnancy appears safe and is associated with lower chances of maternal inflammatory bowel disease (IBD) relapse, without increasing adverse neonatal outcomes, new research suggests.

Oral gonadotropin-releasing hormone (GnRH) antagonists help relieve pain in women with endometriosis or dysmenorrhea, according to the results of a meta-analysis.

Obese adults with weight-related complications who do not respond adequately to lifestyle interventions should be offered one of four anti-obesity medications, according to the new clinical practice guideline on pharmacological interventions released by the American Gastroenterological Association (AGA).

Treatment with nelonemdaz, a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, does not appear to significantly improve stroke outcomes as compared with placebo, although nelonemdaz-treated patients show a greater tendency toward achieving modified Rankin Scale scores of 0–2 at 12 weeks, according to the results of a phase II study.

For women with polycystic ovary syndrome (PCOS), if a 5-day letrozole regimen for ovulation induction does not work, extending the duration of treatment may do the job, as shown in a study.

Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.

The use of the combination of palbociclib plus an aromatase inhibitor (AI) in the first-line treatment setting appears to confer survival advantage on patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC), according to real-world data.